Physician profile
Ankit K Chothani
NPI 1891052072
$12,903.38
in general payments reported to CMS, 2019-2025
26 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,400 · 2021: $1,386 · 2022: $1,071 · 2023: $4,471 · 2024: $2,682 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Travel and Lodging: $4,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.08 |
| Travel and Lodging | $4,095.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $4,233.71 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $2,556.16 | 2022-2025 | Impella |
| Medtronic, INC. | $1,828.35 | 2021-2025 | Abre, Hawkone, Corevalve Evolut R |
| Medtronic Vascular, INC. | $1,231.81 | 2020 | |
| Philips North America LLC | $1,227.09 | 2023-2024 | (Bq9) Coronary Ivus |
| Penumbra, INC. | $598.48 | 2022-2025 | Indigo System |
| Angiodynamics, INC. | $232.07 | 2024-2025 | Alphavac |
| Abbott Laboratories | $160.33 | 2020-2022 | |
| Amgen INC. | $135.77 | 2020-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $116.44 | 2022-2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $71.40 | 2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $67.30 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $59.23 | 2023-2024 | Onpattro |
| Pfizer INC. | $52.08 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $40.92 | 2023-2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.60 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $36.06 | 2022-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $31.54 | 2024 | Venclose Maven Catheter |
| Imperative Care, INC | $30.43 | 2025 | Symphony Catheter |
| Boston Scientific Corporation | $30.12 | 2022-2023 | Synergy |
| Kestra Medical Technology Services, INC. | $28.30 | 2025 | Assure Wcd |
| Stryker Corporation | $27.54 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Flowtriever |
| Cathworks, INC. | $22.94 | 2025 | Ffrangio |
| Astrazeneca Pharmaceuticals LP | $17.53 | 2024 | Farxiga |
| Irhythm Technologies, INC. | $14.97 | 2022 | |
| Cardiovascular Systems INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Chothani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.